INTRODUCTION: Inflammatory processes play an important and complex role in the pathophysiology of major depressive disorder (MDD), but, so far, no specific investigation of chemokines exists. METHODS: In this study, we investigated the changes of plasma chemokine levels (eotaxin-1, eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, and TARC) in 47 MDD patients before (PRE) and after 1 and 6 weeks of pharmacological treatment (POST1 and POST6) in relation to the response to antidepressive therapy. We hypothesized that the direction of alterations in levels of chemokines would significantly differ between the 2 groups, responders and nonresponders. RESULTS: Among the investigated chemokines, only the level of macrophage-derived chemokine (MDC) changed significantly in relation to therapy response. MDC levels were significantly elevated in the responder group at POST6. DISCUSSION: MDC is a constitutively expressed chemokine involved in the pathophysiology of infectious and neoplastic diseases. This is the first study providing valuable hints that MDC might serve as a marker of pharmacological therapy response in MDD.
INTRODUCTION: Inflammatory processes play an important and complex role in the pathophysiology of major depressive disorder (MDD), but, so far, no specific investigation of chemokines exists. METHODS: In this study, we investigated the changes of plasma chemokine levels (eotaxin-1, eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, and TARC) in 47 MDDpatients before (PRE) and after 1 and 6 weeks of pharmacological treatment (POST1 and POST6) in relation to the response to antidepressive therapy. We hypothesized that the direction of alterations in levels of chemokines would significantly differ between the 2 groups, responders and nonresponders. RESULTS: Among the investigated chemokines, only the level of macrophage-derived chemokine (MDC) changed significantly in relation to therapy response. MDC levels were significantly elevated in the responder group at POST6. DISCUSSION: MDC is a constitutively expressed chemokine involved in the pathophysiology of infectious and neoplastic diseases. This is the first study providing valuable hints that MDC might serve as a marker of pharmacological therapy response in MDD.
Authors: Olivia Bauer; Vladimir M Milenkovic; Sven Hilbert; Nina Sarubin; Johannes Weigl; Lisa-Marie Bahr; Thomas C Wetter; Barbara Heckel; Christian H Wetzel; Rainer Rupprecht; Caroline Nothdurfter Journal: Neuroimmunomodulation Date: 2021-01-27 Impact factor: 2.492
Authors: Kaiping Burrows; Jennifer L Stewart; Rayus Kuplicki; Leandra Figueroa-Hall; Philip A Spechler; Haixia Zheng; Salvador M Guinjoan; Jonathan B Savitz; T Kent Teague; Martin P Paulus Journal: Brain Behav Immun Date: 2021-01-26 Impact factor: 19.227
Authors: Vladimir M Milenkovic; Evan H Stanton; Caroline Nothdurfter; Rainer Rupprecht; Christian H Wetzel Journal: Int J Mol Sci Date: 2019-05-09 Impact factor: 5.923
Authors: Rafael Leite Dantas; Jana Freff; Oliver Ambrée; Eva C Beins; Andreas J Forstner; Udo Dannlowski; Bernhard T Baune; Stefanie Scheu; Judith Alferink Journal: Cells Date: 2021-04-19 Impact factor: 6.600
Authors: Heikki Laurikainen; Arja Vuorela; Anna Toivonen; Linnea Reinert-Hartwall; Kalevi Trontti; Maija Lindgren; Jaakko Keinänen; Teemu Mäntylä; Janina Paju; Tuula Ilonen; Reetta-Liina Armio; Maija Walta; Jouni Tuisku; Semi Helin; Päivi Marjamäki; Iiris Hovatta; Sebastian Therman; Outi Vaarala; Outi Linnaranta; Tuula Kieseppä; Raimo K R Salokangas; Jarno Honkanen; Jarmo Hietala; Jaana Suvisaari Journal: Transl Psychiatry Date: 2020-03-16 Impact factor: 6.222